Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Country/Region
    • Clinic Portal
      • +0034963905310
    • Request Information
    • +34 96 390 53 10
    InternationalInternational
    • Country/Region
    • We guide you
      • Fertility
        • What to do if…
      • Prevent Inherited Diseases
        • Carrier Genetic Test
      • Worry-free Pregnancy
        • NACE
        • Prenatal Diagnostics
        • Newborn Health
    • Reproductive Health
      • Specialists
        • ALICE
        • EMMA
        • ERA
        • EndomeTRIO
        • EMBRACE
        • CGT
        • NACE
        • Zenit
        • PGT-A
        • PGT-M
        • POC
        • SAT
        • Newborn Screening
      • Patients
        • ALICE
        • EMMA
        • ERA
        • EndomeTRIO
        • EMBRACE
        • CGT
        • NACE
        • Zenit
        • PGT-A
        • PGT-M
        • SAT
        • POC
    • Diagnostics
    • About us
      • Igenomix Research
      • About Igenomix
    • Academy
    • Blog
        Genomics Precision Diagnostic > Pulmonology > Bronchiectasis and Primary Ciliary Dyskinesia  

        Bronchiectasis and Primary Ciliary Dyskinesia

        Bronchiectasis is a chronic lung disease characterized by a pathologic and irreversible dilation of the airways.
        Overview
        Indication
        Clinical Utility
        Genes & Diseases
        Methodology
        References

        Overview

        • Bronchiectasis is a chronic lung disease characterized by a pathologic and irreversible dilation of the airways. The heterogeneity of bronchiectasis is a major challenge in clinical practice. There are numerous underlying causes of bronchiectasis, although in many cases no cause is found. Known causes include post-infectious, aspiration syndromes, defects in host defence, cystic fibrosis, primary ciliary dyskinesia or even be systemic such as common variable immunodeficiency and anatomical defects including intraluminal airway obstruction, intramural obstruction or external airway compression. Bronchiectasis can be seen in all age groups, but the highest prevalence of disease is seen in the older age range (greater than 60) and women are disproportionately affected.  

        • Primary Ciliary Dyskinesia (PCD) is a genetically and clinically heterogeneous disorder of motile cilia causing failure of mucociliary clearance and organ laterality defects and infertility inherited in an autosomal recessive pattern. It belongs to a rapidly expanding collection of disorders known as ciliopathies. Patients with primary ciliary dyskinesia have diverse clinical manifestations, including chronic upper and lower respiratory tract disease, left-right laterality defects, and infertility. A growing number of disease-associated genes and pathogenic mutations have been identified which encode ciliary structures that allow cilia to be functionally motile.  

        • The Igenomix Bronchiectasis and Primary Ciliary Dyskinesia Precision Panel can be used as a diagnostic tool ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes. 

        Indication

        The Igenomix Bronchiectasis and Primary Ciliary Dyskinesia Precision Panel is indicated in those cases where there is a clinical suspicion or imaging findings with or without the following manifestations:  

        • Cough and daily mucopurulent sputum production  
        • Blood-streaked sputum 
        • Shortness of breath 
        • Pleuritic chest pain 
        • Wheezing 
        • Fever 
        • Weakness 
        • Fatigue 
        • Weight loss 
        • Infertility 
        • Recurrent upper and lower respiratory tract infections 
        • Situs inversus (organ laterality defects) 

        Clinical Utility

        The clinical utility of this panel is:  

        • The genetic and molecular diagnosis for an accurate clinical diagnosis and improve prognosis. 
        • Early initiation of treatment with a multidisciplinary team in the form of prophylactic antibiotics, chest physiotherapy, bronchodilator therapy, and adjunctive surgical resection to improve symptoms, reduce complications and control exacerbations to reduce morbidity and mortality. 
        • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance.

        Genes & Diseases

        Methodology

        References

        See scientific referrals

        Flume, P. A., Chalmers, J. D., & Olivier, K. N. (2018). Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet (London, England), 392(10150), 880–890. https://doi.org/10.1016/S0140-6736(18)31767-7 

        Bush, A., & Floto, R. A. (2019). Pathophysiology, causes and genetics of paediatric and adult bronchiectasis. Respirology (Carlton, Vic.), 24(11), 1053–1062. https://doi.org/10.1111/resp.13509 

        Nikolic A. (2018). Pathophysiology and Genetics of Bronchiectasis Unrelated to Cystic Fibrosis. Lung, 196(4), 383–392. https://doi.org/10.1007/s00408-018-0121-y 

        Knowles, M. R., Zariwala, M., & Leigh, M. (2016). Primary Ciliary Dyskinesia. Clinics in chest medicine, 37(3), 449–461. https://doi.org/10.1016/j.ccm.2016.04.008 

        Editorial, A. (2018). Adult patients with bronchiectasis: clinical guideline of European Respiratory Society. Russian Pulmonology, 28(2), 147-168. doi: 10.18093/0869-0189-2018-28-2-147-168 

        Lucas, J. S., Davis, S. D., Omran, H., & Shoemark, A. (2020). Primary ciliary dyskinesia in the genomics age. The Lancet. Respiratory medicine, 8(2), 202–216. https://doi.org/10.1016/S2213-2600(19)30374-1 

        Horani, A., & Ferkol, T. W. (2018). Advances in the Genetics of Primary Ciliary Dyskinesia: Clinical Implications. Chest, 154(3), 645–652. https://doi.org/10.1016/j.chest.2018.05.007 

        descargar

        Detail description

        Download

        Request Information


        WE GUIDE YOU

        Fertility
        Inherited diseases prevention
        Healthy pregnancy

        To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

        OUR SERVICES

        Genetic solutions
        For patients
        How to send a sample?
        User manual

        ABOUT US

        About Igenomix
        Contact
        Quality
        Complaints
        Work with us

        FOLLOW IGENOMIX

          + 96 390 53 10
          Write us
        • Argentina
        • Brazil
        • Canada
        • Chile
        • Colombia
        • Europe
        • France
        • Germany
        • India
        • Italy
        • Japan
        • Korea
        • Mexico
        • Perú
        • Russia
        • Spain
        • Taiwan
        • The Middle East
        • Turkey
        • United Kingdom
        • United States
        • Vietnam
        Country/Region

        [2021] © Igenomix Privacy policy Quality policy Legal note Cookies policyNews and Press

        Request Information


        • We guide you
          • Fertility
            • What to do if…
          • Prevent Inherited Diseases
            • Carrier Genetic Test
          • Worry-free Pregnancy
            • NACE
            • Prenatal Diagnostics
            • Newborn Health
        • Reproductive Health
          • Specialists
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • Zenit
            • PGT-A
            • PGT-M
            • POC
            • SAT
            • Newborn Screening
          • Patients
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • Zenit
            • PGT-A
            • PGT-M
            • SAT
            • POC
        • Diagnostics
        • About us
          • Igenomix Research
          • About Igenomix
        • Academy
        • Blog
        • Country/Region
        • +34 96 390 53 10
        • Clinic Portal
        • Request Information

        We are using cookies to give you the best experience on our website.

        You can find out more about which cookies we are using or switch them off in settings.

        International
        Powered by  GDPR Cookie Compliance
        Privacy Overview

        This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

        Strictly Necessary Cookies

        Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

        If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

        3rd Party Cookies

        This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

        Keeping this cookie enabled helps us to improve our website.

        Please enable Strictly Necessary Cookies first so that we can save your preferences!

        Cookie Policy

        More information about our Cookie Policy